Edition:
India

Cadila Healthcare Ltd (CADI.NS)

CADI.NS on National Stock Exchange of India

398.50INR
15 Jun 2018
Change (% chg)

Rs-0.20 (-0.05%)
Prev Close
Rs398.70
Open
Rs394.00
Day's High
Rs406.55
Day's Low
Rs393.75
Volume
3,087,095
Avg. Vol
1,226,648
52-wk High
Rs560.00
52-wk Low
Rs341.20

Select another date:

Thu, May 10 2018

BRIEF-Cadila Healthcare Says Zydus Cadila Got USFDA Nod For Drug to Treat Parkinson's Symptoms

* ZYDUS CADILA RECEIVES FINAL APPROVAL FROM USFDA FOR CARBIDOPA TABLETS

BRIEF-Cadila Healthcare Gets Exit Price For Sale Of Shares To Bayer (South East Asia)

* CADILA HEALTHCARE - GOT EXIT PRICE FOR SALE OF SHARES TO BAYER (SOUTH EAST ASIA) PTE LTD IN TERMS OF JV AGREEMENT Source text: http://bit.ly/2HNe3Uu Further company coverage:

BRIEF-Cadila Healthcare Says Zydus Received Final Approval From USFDA For Bumetanide Tablets USP

* SAYS ZYDUS RECEIVED FINAL APPROVAL FROM USFDA FOR BUMETANIDE TABLETS USP Source text for Eikon: Further company coverage:

BRIEF-Cadila Healthcare To Sell 12.5 Mln Shares Of JV To Bayer (South East Asia)

* SAYS CO IS SELLING 12.5 MILLION SHARES OF JV TO BAYER (SOUTH EAST ASIA) PTE BY EXECUTING SHARE PURCHASE DEAL Source text - https://reut.rs/2r4g6ft Further company coverage:

BRIEF-Cadila Healthcare Says Zydus Gets U.S. FDA Final Nod For Methylprednisolone Tablets USP, Cinacalcet Hydrochloride Tablets

* SAYS ZYDUS GETS FINAL APPROVAL FROM USFDA FOR METHYLPREDNISOLONE TABLETS USP AND CINACALCET HYDROCHLORIDE TABLETS Source text - http://bit.ly/2Hry5Yw Further company coverage:

BRIEF-Cadila Healthcare Says Zydus Gets Final Approval From U.S. FDA For Diclofenac Sodium Topical Solution

* SAYS ZYDUS GETS FINAL APPROVAL FROM U.S. FDA FOR DICLOFENAC SODIUM TOPICAL SOLUTION

BUZZ-CY 2018 to be volatile for Indian stock markets - Citi

** Calendar year 2018 will be volatile for Indian stock markets, says Citi

MEDIA-India's Cadila Healthcare appeals against Delhi High Court order refusing to stay CCI verdict - Mint

- Note: Reuters has not verified this story and does not vouch for its accuracy

BRIEF-India's Cadila Healthcare Says No Observation Issued For Topical Unit

* SAYS TOPICAL FACILITY SUCCESSFULLY COMPLETES USFDA INSPECTION

BRIEF-Cadila Healthcare Says ‍Zydus Gets U.S. FDA Nod For Metoprolol Succinate Extended-Release Tablets USP​

* SAYS ‍ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR METOPROLOL SUCCINATE EXTENDED-RELEASE TABLETS USP​ Source text - http://bit.ly/2pEyVGd Further company coverage:

Select another date: